New recommendation on meningitis vaccines for

<p>University of Maryland School of Medicine (UMSOM) researchers, as part of the Infectious Diseases Clinical Research Consortium (IDCRC), provided an interim analysis showing that the pentavalent (NmCV-5) meningitis vaccine is safe for use in 9-month-old infants in the meningitis belt of sub-Saharan Africa.&nbsp;They presented their results to the World Health Organization&rsquo;s (WHO) Strategic Advisory Group of Experts (SAGE) on Immunization on September 26.&nbsp;SAGE recommended&nbsp;that all countries in the African meningitis belt introduce the novel pentavalent meningococcal conjugate vaccine targeting serogroups A, C, Y, W and X (Men5CV) into their routine immunization programs in a single-dose schedule at 9 to 18 months of age.&nbsp;</p>

Related Keywords

Cincinnati ,Ohio ,United States ,University Of Cincinnati ,Karen Kotloff ,Wilbur Chen ,Kaiser Permanente Washington Health Research Institute ,Vanderbilt University Medical Center ,National Institute Of Allergy ,Strategic Advisory Group Of Experts ,Cincinnati Children Medical Center ,University Of Alabama At Birmingham ,University Of Maryland School Medicine ,Vaccine Development ,University Of Washington ,Emory University ,Global Health ,Baylor College Of Medicine ,Fred Hutchinson Cancer Research Center ,Infectious Disease Clinical Research Consortium ,University Of Rochester ,Leadership Group ,York University ,National Institutes Of Health ,Infectious Diseases Clinical Research Consortium ,Johns Hopkins University ,Saint Louis University ,Method Of Research ,World Health Organization ,Maryland School ,Strategic Advisory Group ,Saharan Africa ,Vaccine Treatment ,Evaluation Unit ,Vaccine Development Mali ,National Institute ,Infectious Diseases ,National Institutes ,Evaluation Units ,Baylor College ,Cincinnati Children ,Medical Center ,New York University ,Medicine Vaccine Treatment ,Treatment Evaluation Units ,